2341 Tumor genotyping and clonal evolution in KIT during regorafenib treatment in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST. (September 2015) - Jeffers, M.; Beckmann, G.; Reischl, J.; Rutstein, M.; Wagner, A.; Demetri, G.D.; Teufel, M.